Longterm Drug Survival of Tumor Necrosis Factor Inhibitors in Patients with Rheumatoid Arthritis.
Paul EmeryBonnie VlahosPiotr SzczypaMazhar ThakurHeather E JonesJohn WoolcottPaul V Santos EstrellaCatherine RollandAllan GibofskyGustavo CiteraSargunan SockalingamLisa MarshallPublished in: The Journal of rheumatology (2019)
After > 12 months of followup, more patients with RA receiving ETN remain on treatment compared with other tumor necrosis factor inhibitors.